Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPX-101 in Cystic Fibrosis
NCT03229252Phase 2Completed
- Sponsor
- Spyryx Biosciences
- Start
- Aug 2017
- Primary completion
- Jun 2019
- Modality
- Peptides, Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of SPX-101 in cystic fibrosis (CF) (3 arms), sponsored by Spyryx Biosciences. Primary endpoint: Change in Percent Predicted Forced Expiratory Volume in 1 Second at Day 28. Started Aug 2017; status: completed.
02
Drugs
SPX-101
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03229252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03229252.